Clinical Trial Update: A Pilot Therapeutic Trial Using Hydroxyurea in Type II and Type III Spinal Muscular Atrophy Patients [Phase 1, Phase 2]

View source ↗

Summary

Pilot therapeutic trial evaluating hydroxyurea in Type II and Type III spinal muscular atrophy patients completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy

Drugs mentioned

• HYDROXYUREA (Hydroxyurea)

Snippet

Sponsor: Stanford University | Conditions: Muscular Atrophy, Spinal | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-10-02